OOIR: Observatory of International Research

Papers

(The TQCC of Liver International is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Comparison of MAFLD and NAFLD diagnostic criteria in real world	358
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	279
Pathophysiological mechanisms of liver injury in COVID‐19	265
COVID‐19 and liver disease	232
Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations	209
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review	158
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population	135
Changing epidemiology of hepatocellular carcinoma in Asia	118
Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience	108
Abnormal liver function tests predict transfer to intensive care unit and death in COVID‐19	96
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19	89
SARS‐CoV‐2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID‐19	86
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis	83
Hepatic macrophages: Key players in the development and progression of liver fibrosis	80
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis	79
Metabolic‐associated fatty liver disease is associated with severity of COVID‐19	75
Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis	74
The changing scenario of hepatocellular carcinoma in Italy: an update	72
Radiomics in liver diseases: Current progress and future opportunities	68
Diet and exercise in NAFLD/NASH: Beyond the obvious	67
Hepatitis E: An update on One Health and clinical medicine	67
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts	65
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	61
Bilirubin levels in patients with mild and severe Covid‐19: A pooled analysis	61
The NAFLD‐MAFLD debate: Eminence vs evidence	60

Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	60
Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19	58
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH	52
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation	50
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia	50
Treatment and the prognosis of hepatocellular carcinoma in Asia	47
Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group	47
Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study	46
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	46
LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases	45
Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study	44
MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study	44
Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis	43
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis	43
Exploring the landscape of steatotic liver disease in the general US population	43
Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China an	43
Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study	43
The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy	42
Potential implications of COVID‐19 in non‐alcoholic fatty liver disease	42
Immune‐related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors	42
High‐protein diet more effectively reduces hepatic fat than low‐protein diet despite lower autophagy and FGF21 levels	42
Incidence and risk factors of drug‐induced liver injury	41
A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction	41
Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study	39
Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?	39
Incidence, prevalence and mortality of autoimmune hepatitis in England 1997‐2015. A population‐based cohort study	39
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma	37
2021 ISHEN guidelines on animal models of hepatic encephalopathy	37
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease	37
Association of genetic variations with NAFLD in lean individuals	36
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life	36
Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States	36
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives	36
Safety of direct oral anticoagulants in patients with advanced liver disease	36
Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection	35
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study	34
Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)	34
HBV 2021: New therapeutic strategies against an old foe	34
Liver involvement in children with SARS‐COV‐2 infection: Two distinct clinical phenotypes caused by the same virus	34
MAFLD vs NAFLD: Let the contest begin!	34
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…	34
Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury	33
Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease	33
New drugs for NASH	33
Management of NAFLD in primary care settings	33
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	33
Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI	32
Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients	32
Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD	32
Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients	32

Lymphocyte‐C‐reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study	32
COVID‐19 and the liver: A 2021 update	31
Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease	31
Role of fibroblast growth factor signalling in hepatic fibrosis	31
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	31
Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review	31
Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus	31
Acceptance and use of a smartphone application in cirrhosis	31
Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?	30
The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt	30
GES: A validated simple score to predict the risk of HCC in patients with HCV‐GT4‐associated advanced liver fibrosis after oral antivirals	30
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry	30
Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study	29
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease	29
Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection	29
The association of sex steroid hormone concentrations with non‐alcoholic fatty liver disease and liver enzymes in US men	29
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure	29
From NAFLD to MAFLD: Nurse and allied health perspective	29
Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation	29
Integrins as a drug target in liver fibrosis	29
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma	29
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan	29
Rodent models of cholestatic liver disease: A practical guide for translational research	29
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia	28
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip	28
Machine‐learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection	28
MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease	27
Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence	27
Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high‐risk patients	27
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	27
The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria	27
Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population	27
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis	27
Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma	27
Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension	27
Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity	26
Nationwide treatment and outcomes of perihilar cholangiocarcinoma	26
PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD	26
Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure: A propensity‐score matched study from AARC	26
Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma	26
Hepatocyte‐derived MANF alleviates hepatic ischaemia‐reperfusion injury via regulating endoplasmic reticulum stress‐induced apoptosis in mice	25
Effects of two personalized dietary strategies during a 2‐year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial	25
Concordance between MAFLD and NAFLD diagnostic criteria in ‘real‐world’ data	25
Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD	25
Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids	25
Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study	25
Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar	25
Functional rescue of an ABCB11 mutant by ivacaftor: A new targeted pharmacotherapy approach in bile salt export pump deficiency	25
Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens	25
Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36	25
Road to elimination of HCV: Clinical challenges in HCV management	25
Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience	24
The role of hepatic lipid composition in obesity‐related metabolic disease	24
Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation	24
Safety of fibrates in cholestatic liver diseases	24
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events	24
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	24
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2	24
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis	24
Association between non‐alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study	24
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis	24
Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes	24
COVID‐19 and viral hepatitis elimination programs: Are we stepping backward?	23
Deep learning for noninvasive liver fibrosis classification: A systematic review	23
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	23
Bariatric surgery and the risk of alcohol‐related cirrhosis and alcohol misuse	23
Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis	23
Normal liver stiffness and influencing factors in healthy children: An individual participant data meta‐analysis	23
Interferon‐based treatment of chronic hepatitis D	22
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma	22
Cellular senescence and hepatitis B‐related hepatocellular carcinoma: An intriguing link	22
Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non‐alcoholic fatty liver disease	22
Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use	22
Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination	22
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis	21
Influence of donor and recipient gender on liver transplantation outcomes in Europe	21
Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance	21
The association of non‐alcoholic fatty liver disease and cardiac structure and function—Framingham Heart Study	21
Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies	21
Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats	21

Chanarin‐Dorfman Syndrome: A comprehensive review	21
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease	21
Contrast‐enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta‐analysis	21
The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population	21
Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry?	21
Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma	21
Liver transplantation for acute‐on‐chronic liver failure predicts post‐transplant mortality and impaired long‐term quality of life	21
Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets	21
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients	20
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice	20
Hepatitis B virus‐related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non‐viral risk factors	20
Paradigm shift in the treatment options of hepatocellular carcinoma	20
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab	20
COVID‐19 and the liver – Lessons learned	20
Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study	20
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects	20
Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta‐analysis	20
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis	20
A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?	20
Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor	20
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)	19
SPARC inhibition accelerates NAFLD‐associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism	19
m⁵C and m⁶A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis	19
Contribution of a genetic risk score to ethnic differences in fatty liver disease	19
High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma	19
Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial	19
New therapies for hepatitis delta virus infection	19
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	19
NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction	19
HCC advances in diagnosis and prognosis: Digital and Imaging	19
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B	18
Epidemiology and surveillance of autoimmune hepatitis in Asia	18
Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma	18
Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease	18
Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation	18
Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease	18
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	18
Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population‐based study	18
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study	18
Sarco‐Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation	18
Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort	18
Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era	18
Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis	18
TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy	18
Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4	18
Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study	18
Natural history of NASH	18
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea	18
The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue	18
YAP‐induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer	17
Exosome‐derived differentiation antagonizing non‐protein coding RNA with risk of hepatitis C virus‐related hepatocellular carcinoma recurrence	17
Changing clinical management of NAFLD in Asia	17
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis	17
Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes	17
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications	17
Non‐selective beta‐blockers in patients with ascites: The complex interplay among the liver, kidney and heart	17
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles	17
Co‐expression of IL‐7 and PH20 promote anti‐GPC3 CAR‐T tumour suppressor activity in vivo and in vitro	17
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment	17
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	17
The global trends and regional differences in incidence of HEV infection from 1990 to 2017 and implications for HEV prevention	17
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries	17
LGR5 induces β‐catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma	17
Pregnancy outcome of anti‐HCV direct‐acting antivirals: Real‐life data from an Egyptian cohort	17
A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity	17
Implication of CD69⁺CD103⁺ tissue‐resident‐like CD8⁺ T cells as a potential immunotherapeutic target for cholangiocarcinoma	16
Estrogens in polycystic liver disease: A target for future therapies?	16
Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review	16
New insights in the management of Hepatocellular Adenoma	16
Rates and characteristics of SARS‐CoV‐2 infection in persons with hepatitis C virus infection	16
Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population‐based study	16
Impact on follow‐up strategies in patients with primary sclerosing cholangitis	16
Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma	16
Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis	16
Integration of miRNA‐regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease	16
Metabolic‐associated fatty liver disease (MAFLD) in coeliac disease	16
Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents	16
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	16
Liver regeneration: Cellular origin and molecular mechanisms	16
Quality of life, caregiver burden and mental health disorders in primary caregivers of patients with Cirrhosis	16
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements	16
Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE)	15
Liver transplantation in patients with liver failure: Twenty years of experience from China	15
Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice	15
Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis	15
Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel	15
Liver injury caused by oral anticoagulants: A population‐based retrospective cohort study	15
The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint	15
High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation	15
Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis	15
A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017	15
Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma	15
Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease	15
Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study	15
Causal relationships between metabolic‐associated fatty liver disease and iron status: Two‐sample Mendelian randomization	15